In thinking about the new ultrasensitive troponin I tests under development (e.g. Singulex, Nanosphere) that might have diagnostic applications for routine screening or assessment of high-risk individuals, what initial clinical data/studies would be needed for you (physician) to send a patients sample to be processed in a CLIA laboratory. I appreciate that large prospective studies will eventually be required for adoption, but are there initial retrospective or comparative studies that would generate interest? I would appreciate any specifics in terms of sample type, inclusion/exclusion, specimen numbers, primary outcome measures etc. that would be important. Many thanks.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.